PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
NCT ID: NCT06320223
Last Updated: 2024-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2024-03-05
2035-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.
Need:
Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.
Aim:
1. To assess the prognostic value of PSMA PET
2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages
Inclusion:
* Adult patients with
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
NCT03976843
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584
Identification of Predictive Biomarkers
NCT04324983
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms
NCT06835244
MRI in Diagnosing Prostate Cancer
NCT01292291
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) Positron-Emission-Tomography (PET) whole-body stage of prostate cancer \[Seifert et al. European Urology 2023\]. PSMA PET disease extent by PROMISE has been associated with relevant oncologic outcome, specifically overall survival in patients with various stages of prostate cancer.
Need:
Improved risk assessment across various stages of prostate cancer is urgently needed for guidance of clinical management and prospective study design.
Aim:
1. To assess the prognostic value of PSMA PET, summarized by PROMISE \[Seifert et al EurUrol23\]
2. To compare the prognostic value of PSMA PET with established clinical prognostic scores in patients with prostate cancer at various disease stages
3. To assess the association of PSMA PET stage with management, laboratory findings, histopathology findings or patient characteristics
Eligibility:
Adult patients with biopsy/histo proven prostate cancer who underwent PSMA PET for staging at various stages will be included consecutively. All stages will be included: Primary (Initial Staging), BCR (Biochemical Recurrence), nmCRPC (conventional non-metastatic castration-resistant prostate cancer), mHSPC (conventional metastatic hormone-sensitive prostate cancer), mCRPC (conventional metastatic castration-resistant prostate cancer) and advanced mCRPC.
Inclusion:
* Adult patients with
* histopathology proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer
Statistical considerations:
This is an open registry study. The more data sets are contributed, the more precisely the diagnostic accuracy and prognostic value of PSMA PET can be determined for the overall cohort and subgroups.
Prognostic value of variables from PSMA-PET (PROMISE parameters, PSMA-Volume, Standardized Uptake Value (SUV) among other) and patient characteristics will be assessed by regression analysis and correlation analysis. Hazard ratio (95% Confidence Interval) and Concordance Index for the prediction of primary and secondary endpoints will be calculated. Primary endpoint is the association with overall survival. Secondary endpoints are the association with progression-free survival, management and other characteristics.
Central Database:
Data will be stored centrally in a RedCap Database with 3-step authentication at the sponsor site.
Recurring Data Entry:
Data entry will be conducted repeatedly at about 3 to 6 month intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostate cancer patients with PSMA PET
Inclusion:
* Adult patients with
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wolfgang P Fendler, M.D.
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Essen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Essen
Essen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Karpinski MJ, Husing J, Claassen K, Moller L, Kajuter H, Oesterling F, Grunwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Husing A, Kesch C, Herrmann K, Eiber M, Hoberuck S, Meyer PT, Kind F, Rahbar K, Schafers M, Stang A, Hadaschik BA, Fendler WP. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024 Sep;25(9):1188-1201. doi: 10.1016/S1470-2045(24)00326-7. Epub 2024 Jul 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROMISE PET Registry
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.